Advertisement
News
Advertisement

Biogen ends collaboration with Cardiokine

Thu, 11/04/2010 - 12:35pm
Mass High Tech: The Journal of New England Technology

Biogen Idec Inc. and its Philadelphia-based partner Cardiokine Inc. have ended a collaboration on lixivaptan, a drug candidate for hyponatremia, or low sodium levels in the blood.

As a result, Cardiokine will regain all rights to the drug candidate, which is in Phase 3 clinical development.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading